Kistner, Alexander
Chichester, Jessica A.
Wang, Lili http://orcid.org/0000-0001-9347-3939
Calcedo, Roberto
Greig, Jenny A.
Cardwell, Leah N. http://orcid.org/0000-0001-9491-7749
Wright, Margaret C.
Couthouis, Julien http://orcid.org/0000-0002-2378-4595
Sethi, Sunjay
McIntosh, Brian E.
McKeever, Kathleen
Wadsworth, Samuel
Wilson, James M. http://orcid.org/0000-0002-9630-3131
Kakkis, Emil
Sullivan, Barbara A. http://orcid.org/0000-0003-0969-6131
Funding for this research was provided by:
Ultragenyx Pharmaceutical
Article History
Received: 2 March 2023
Revised: 7 September 2023
Accepted: 28 September 2023
First Online: 13 October 2023
Competing interests
: AK, LNC, JC, MW, KM, SW, EK, and BAS are employees of Ultragenyx Pharmaceutical Inc. LW, JAG, and JMW are inventors on patents that have been licensed to various biopharmaceutical companies and for which they may receive payments. RC is an employee of Affinia Therapeutics Inc. JMW is a paid advisor to and holds equity in iECURE, Scout Bio, Passage Bio, and the Center for Breakthrough Medicines (CBM). He also holds equity in the former G2 Bio asset companies. He has sponsored research agreements with Amicus Therapeutics, CBM, Elaaj Bio, FA212, former G2 Bio asset companies, iECURE, Passage Bio, and Scout Bio, which are licensees of Penn technology. BEM is an employee of Labcorp Drug Development. JAC and SS declare no competing interests.
: Animal procedures were approved by the Labcorp Institutional Animal Care and Use Committee.